Pharmaceuticals

ASK PHARM

ASK PHARM released FY2026 Q1 earnings on April 28 Pre-Market (BJT), actual revenue CNY 481.78 M, actual EPS CNY 0.09

ASK PHARM released FY2025 Q4 earnings on April 28 After-Market BJT, with actual revenue of CNY 345.13 M and EPS of CNY 0.0133

ASK PHARM released FY2025 annual earnings on April 28 After-Market (BJT), actual revenue CNY 1.779 B (forecast CNY 2.037 B), actual EPS CNY 0.25 (forecast CNY 0.18)

ASK PHARM FY2026 Q1 Earning Release on April 29 Pre-Market BJT

ASK PHARM to release FY2025 earnings on April 29 After-Market (BJT), forecast revenue CNY 2.037 B, EPS CNY 0.18

ASK PHARM released FY2025 Q3 earnings on October 28, 2025 (BJT), with actual revenue of CNY 426.48 M and EPS of CNY 0.0696

ASK PHARM released FY2025 9 Months earnings on October 28, 2025 (BJT), with actual revenue of CNY 1.434 B and actual EPS of CNY 0.2381

ASK PHARM released FY2025 Semi-Annual Earnings on August 28 Pre-Market (BJT), with actual revenue of CNY 1.007 B and EPS of CNY 0.17

ASK PHARM released FY2025 Q2 earnings on August 28 Pre-Market (BJT), actual revenue CNY 498.86 M, actual EPS CNY 0.1085

ASK PHARM to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Jiangsu SuYang plans to 减持 1.5% of Oscient's shares

Osaike Stock Undergoes Block Trade

Oushike Kang's Net Profit Expected to Grow by 78.58%-131.50% in the First Half of 2025

TF Securities Gives Oasisky a Buy Rating

Osconk's Innovative Cytokine Therapy to Drive Future Growth

ASK PHARM released FY2025 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 508.56 M, actual EPS CNY 0.06

ASK PHARM released FY2024 Q4 earnings on April 27 After-Market BJT, actual revenue CNY 393.19 M, actual EPS CNY 0.0316

ASK PHARM released FY2024 earnings on April 27 After-Market (BJT), actual revenue CNY 1.778 B (forecast CNY 1.773 B), actual EPS CNY 0.17 (forecast CNY 0.03)

ASK PHARM to Release FY2025 Q1 Earnings Report on April 28 After-Market BJT

ASK PHARM to release FY2024 earnings report on April 28, 2025, after-market BJT, with forecast revenue of CNY 1.773 B and EPS of CNY 0.03

300361

002755

According to the Zhitong Finance APP, ASK PHARM released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.434 billion yuan, a year-on-year increase of 3.57%. The net profit attributable to shareholders of the listed company was 223 million yuan, a year-on-year increase of 75.81%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 186 million yuan, a year-on-year increase of 81.89%

Zhitong

Aosaikang

ASK PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 223 million yuan, a year-on-year increase of 75.81%

ASK PHARM announced that its subsidiary ASKGENE LIMITED will present clinical research data for the biopharmaceutical ASKB589 at the 2025 ESMO Annual Meeting. The drug, in combination with CAPOX and PD-1 inhibitors, has shown deep and lasting tumor remission and disease control in first-line treatment of advanced gastric cancer, with clear survival benefits. These positive clinical data will enhance the market competitiveness of the company's products

Aosaikang: Innovative drug ASKB589 will announce clinical research data at the 2025 ESMO Annual Meeting

Aosaikang's holding subsidiary AskGene Pharma has signed a licensing agreement with Visara, allowing Visara to use the independently developed innovative drug ASKG712 in specific regions. This drug targets VEGF and ANG-2 and is currently undergoing Phase IIa clinical trials in China, showing good safety and efficacy. This collaboration will promote the research and commercialization of ASKG712, aligning with the company's strategic direction and is expected to have a positive impact on future performance

Aosaikang's subsidiary signs ASKG712 project licensing agreement

300204

600276

688513

300111

The pharmaceutical sector fell at the beginning of trading, with SUNFLOWER dropping 10%, ASK PHARM falling over 7%, and multiple stocks including Staidson BioPharm, Hengrui Pharma, and EASTON BIOPHARMACEUTICALS declining

Staidson BioPharm

Hengrui Pharma

EASTON BIOPHARMACEUTICALS

SUNFLOWER

The pharmaceutical sector fell at the beginning of trading, with SUNFLOWER dropping 10%

300436

300006

688428

09969

The pharmaceutical sector fluctuated and strengthened, with ASK PHARM hitting the limit up, SUNFLOWER rising over 13%, and Cosunter, Xinlitai, Lummy, and INNOCARE among the top gainers

Cosunter

Lummy

InnoCare Pharma

INNOCARE

The pharmaceutical sector fluctuates and strengthens, ASK PHARM hits the limit up

According to the Zhitong Finance APP, ASK PHARM announced that the first patient has been dosed in the registrational Phase III clinical study of the Class 1 innovative drug ASKC202, developed by its wholly-owned subsidiary Jiangsu ASK PHARM Co., Ltd., in combination with Lapatinib for the treatment of locally advanced or metastatic non-small cell lung cancer with MET amplification/overexpression after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI)

ASK PHARM: Innovative drug ASKC202 completes first patient dosing in Phase III registration clinical study

Aosaikang announced that in the first half of 2025, operating revenue reached 1.007 billion yuan, a year-on-year increase of 9.20%. Net profit was 160 million yuan, a year-on-year increase of 111.64%

Aosaikang: Net profit of 160 million yuan in the first half of 2025, a year-on-year increase of 111.64%

According to the announcement from ASK PHARM, Su Yang Investment plans to reduce its holdings in the company by no more than 13.9224 million shares, not exceeding 1.5% of the company's total share capital, through centralized bidding and block trading within 90 calendar days after the 15 trading days from the date of this announcement

ASK PHARM: Su Yang Investment plans to reduce its holdings of no more than 1.5% of the company's shares

Aosaikang announced that the cumulative closing price deviation of its stock exceeded 20% over two consecutive trading days on July 15 and 16, 2025, which constitutes abnormal volatility. After verification, the company found no information that needs correction, recent operating conditions are normal, there have been no significant changes in the internal and external environment, and there are no undisclosed significant matters

Aosaikang: Abnormal fluctuations in stock trading

Aosaikang announced that it expects a net profit of 135 million to 175 million yuan in the first half of 2025, an increase of 78.58% to 131.50% compared to 75.5945 million yuan in the same period last year

Aosaikang: Expected net profit in the first half of the year to increase by 78.58%-131.50% year-on-year

ASK PHARM(002755.SZ)